title: Metabolic screening in vitro: metabolic stability, CYP inhibition and induction.
abstract: Automated, miniaturised assays are now commonplace within Discovery DMPK (drug metabolism and pharmacokinetics). These have evolved considerably since their inception around a decade ago, in-line with both technology and the desire to provide quality data comparable to more traditional analyses. Several formats exist for routine screening of metabolic stability and cyp (cytochrome P450; see Glossary) inhibition and induction, with the major focus being on in vitro systems using human-derived material. Data from other species remain valuable in assessing in vitro-in vivo projections and are pivotal to support safety assessment studies.:
authors: Department of Physical and Metabolic Science, AstraZeneca R&D Charnwood, Loughborough, Leics, UK LE11 5RH. Electronic address:rob.riley@astrazeneca.com.
authors: Robert J
authors: RJ
authors: Riley
authors: Department of Physical and Metabolic Science, AstraZeneca R&D Charnwood, Loughborough, Leics, UK LE11 5RH.
authors: Ken
authors: K
authors: Grime